EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews

Gemma Cupples, Emanuel Krebs iD, Deirdre Weymann, Cheryl Ho, Dean A Regier iD

International Journal of Technology Assessment in Health Care · 2025

DOI: 10.1017/s0266462325100111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, 2025. Verfasst von Gemma Cupples und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regulatory Science Lab, https://ror.org/03sfybe47BC Cancer Research Institute, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Neoplasms, Benzamides, Precision Medicine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Life-cycle health technology assessment (HTA) requires an index economic model to establish how estimated cost-effectiveness evolves with emerging evidence. We developed an open-source index economic evaluation of entrectinib, a tumor-agnostic therapy with conditional market authorization. Our objective was to replicate the initial HTA report from publicly available information, aiming to identify key operational and methodological aspects for operationalizing life-cycle decision-making.

Methods

We used partitioned survival analysis to determine tumor-agnostic and tumor-specific cost-effectiveness, using publicly available HTA reviews for parameterization. We estimated incremental costs in 2021 Canadian and US dollars (CAD and USD) from a public-payer healthcare perspective, quality-adjusted life years (QALYs), and incremental net monetary benefit (INMB). We assessed the impact of treatment effectiveness, extrapolation assumptions, and next-generation sequencing (NGS) costs.

Results

One-third of the parameters ( n = 30) were unavailable in the Canadian reimbursement review and were sourced from international reviews. Tumor-agnostic incremental costs were CAD 68,451 (95 percent confidence interval: 35,466, 92,155) and USD 54,608 (28,294, 73,518), and QALYs were 0.13 (−0.42, 0.42), yielding INMB CAD −55,803 at 100,000/QALY (USD −44,518). Full extrapolation of treatment effectiveness also yielded negative INMB (CAD −66,664). Inclusion of NGS costs diminished the expected value. Heterogeneity was considerable across tumor indications.

Conclusions

We developed an open-source index economic evaluation to operationalize life-cycle HTA for a conditionally authorized tumor-agnostic therapy. Our findings outline key operational and methodological considerations necessary for the development of index economic models that support life-cycle HTA, offering insights into their potential integration into regular HTA and policy decision-making processes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalNeoplasmsBenzamidesPrecision MedicineAntineoplastic AgentsHumansCost-Benefit AnalysisQuality-Adjusted Life YearsCanadaModels, EconomicSurvival Analysis

Stichwörter der Autor:innen

economic evaluationhealth technology assessmentlife-cycle HTAprecision oncologytumor-agnostic therapies

Substanzen

BenzamidesAntineoplastic Agents

Autor:innen und Institutionen

  • Regulatory Science Lab, https://ror.org/03sfybe47BC Cancer Research Institute, Vancouver, BC, Canada.
  • Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada.
  • Department of Medical Oncology, https://ror.org/03sfybe47BC Cancer, Vancouver, BC, Canada.
  • Department of Medicine, Faculty of Medicine, https://ror.org/03rmrcq20University of British Columbia, Vancouver, BC, Canada.
  • School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

ORCID-Profile: Emanuel Krebs, Dean A Regier

Zitieren

APA

Cupples, G., Krebs, E., Weymann, D., Ho, C., & Regier, D. A. (2025). Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462325100111

Vancouver

Cupples G, Krebs E, Weymann D, Ho C, Regier DA. Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews. International Journal of Technology Assessment in Health Care. 2025. doi:10.1017/s0266462325100111

BibTeX
@article{Cupples2025,
  author = {Cupples, Gemma and Krebs, Emanuel and Weymann, Deirdre and Ho, Cheryl and Regier, Dean A},
  title = {Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews},
  journal = {International Journal of Technology Assessment in Health Care},
  year = {2025},
  doi = {10.1017/s0266462325100111}
}
Kostenlos starten →